Patents by Inventor Markus Stoffel
Markus Stoffel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220202847Abstract: The invention relates to double stranded ribonucleic acid (dsRNA) agents and compositions targeting a High Density Lipoprotein Binding Protein (Hdlbp/Vigilin) gene, as well as methods of inhibiting expression of Hdlbp/Vigilin and methods of treating subjects having a disorder of lipid metabolism, such as mixed hyperlipidemia, hypertriglyceridemia or hypercholesterolemia, using such dsRNA agents and compositions.Type: ApplicationFiled: November 17, 2021Publication date: June 30, 2022Applicants: Alnylam Pharmaceuticals, Inc., ETH ZurichInventors: Muthiah Manoharan, Markus Stoffel, Mehrpouya Balaghy Mobin
-
Patent number: 11207342Abstract: The invention relates to double stranded ribonucleic acid (dsRNA) agents and compositions targeting a High Density Lipoprotein Binding Protein (Hdlbp/Vigilin) gene, as well as methods of inhibiting expression of Hdlbp/Vigilin and methods of treating subjects having a disorder of lipid metabolism, such as mixed hyperlipidemia, hypertriglyceridemia or hypercholesterolemia, using such dsRNA agents and compositions.Type: GrantFiled: October 17, 2018Date of Patent: December 28, 2021Assignees: Alnylam Pharmaceuticals, Inc., ETH ZurichInventors: Muthiah Manoharan, Markus Stoffel, Mehrpouya Balaghy Mobin
-
Patent number: 10287589Abstract: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.Type: GrantFiled: February 20, 2018Date of Patent: May 14, 2019Assignee: ETH ZurichInventors: Markus Stoffel, Mirko Trajkovski
-
Publication number: 20190038658Abstract: The invention relates to double stranded ribonucleic acid (dsRNA) agents and compositions targeting a High Density Lipoprotein Binding Protein (Hdlbp/Vigilin) gene, as well as methods of inhibiting expression of Hdlbp/Vigilin and methods of treating subjects having a disorder of lipid metabolism, such as mixed hyperlipidemia, hypertriglyceridemia or hypercholesterolemia, using such dsRNA agents and compositions.Type: ApplicationFiled: October 17, 2018Publication date: February 7, 2019Inventors: Muthiah Manoharan, Markus Stoffel, Mehrpouya Balaghy Mobin
-
Publication number: 20180251766Abstract: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.Type: ApplicationFiled: February 20, 2018Publication date: September 6, 2018Applicant: ETH ZurichInventors: Markus Stoffel, Mirko Trajkovski
-
Patent number: 9932595Abstract: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.Type: GrantFiled: December 12, 2016Date of Patent: April 3, 2018Assignee: ETH ZurichInventors: Markus Stoffel, Mirko Trajkovski
-
Publication number: 20170218368Abstract: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.Type: ApplicationFiled: December 12, 2016Publication date: August 3, 2017Applicant: ETH ZurichInventors: Markus Stoffel, Mirko Trajkovski
-
Patent number: 9550996Abstract: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluconeogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.Type: GrantFiled: December 16, 2015Date of Patent: January 24, 2017Assignee: ETH ZurichInventors: Markus Stoffel, Mirko Trajkovski
-
Publication number: 20160208259Abstract: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.Type: ApplicationFiled: December 16, 2015Publication date: July 21, 2016Applicant: ETH ZurichInventors: Markus Stoffel, Mirko Trajkovski
-
Patent number: 9382539Abstract: The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.Type: GrantFiled: November 30, 2015Date of Patent: July 5, 2016Assignee: The Rockefeller UniversityInventors: Markus Stoffel, Matthew N. Poy, Thomas H. Tuschl
-
Publication number: 20160138020Abstract: The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.Type: ApplicationFiled: November 30, 2015Publication date: May 19, 2016Inventors: Markus Stoffel, Matthew N. Poy, Thomas H. Tuschl
-
Patent number: 9243249Abstract: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.Type: GrantFiled: July 18, 2014Date of Patent: January 26, 2016Assignee: ETH ZURICHInventors: Markus Stoffel, Mirko Trajkovski
-
Patent number: 9200290Abstract: The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.Type: GrantFiled: March 10, 2014Date of Patent: December 1, 2015Assignee: The Rockefeller UniversityInventors: Markus Stoffel, Matthew N. Poy, Thomas H. Tuschl
-
Publication number: 20150038550Abstract: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.Type: ApplicationFiled: July 18, 2014Publication date: February 5, 2015Inventors: Markus Stoffel, Mirko Trajkovski
-
Patent number: 8877730Abstract: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.Type: GrantFiled: October 23, 2013Date of Patent: November 4, 2014Assignee: ETH ZurichInventors: Markus Stoffel, Mirko Trajkovski
-
Publication number: 20140227778Abstract: The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.Type: ApplicationFiled: March 10, 2014Publication date: August 14, 2014Applicant: The Rockefeller UniversityInventors: Markus Stoffel, Matthew N. Poy, Thomas H. Tuschl
-
Publication number: 20140113953Abstract: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.Type: ApplicationFiled: October 23, 2013Publication date: April 24, 2014Applicant: ETH ZURICHInventors: Markus Stoffel, Mirko Trajkovski
-
Patent number: 8697859Abstract: The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.Type: GrantFiled: January 18, 2013Date of Patent: April 15, 2014Assignee: The Rockefeller UniversityInventors: Markus Stoffel, Matthew N. Poy, Thomas H. Tuschl
-
Publication number: 20140073684Abstract: This invention relates generally to chemically modified oligonucleotides useful for modulating expression of microRNAs and pre-microRNAs. More particularly, the invention relates to single stranded chemically modified oligonucleotides for inhibiting microRNA and pre-microRNA expression and to methods of making and using the modified oligonucleotides. Also included in the invention are compositions and methods for silencing microRNAs in the central nervous system.Type: ApplicationFiled: August 27, 2013Publication date: March 13, 2014Applicants: Alnylam Pharmaceuticals, Inc., The Rockefeller UniversityInventors: Markus Stoffel, Muthiah Manoharan, Kallanthottathil G. Rajeev
-
Patent number: 8592388Abstract: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.Type: GrantFiled: May 19, 2010Date of Patent: November 26, 2013Assignee: ETH ZurichInventors: Markus Stoffel, Mirko Trajkovski